Morgan Stanley analyst Vincent Andrews maintained a Buy rating on Corteva yesterday and set a price target of $84.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Vincent Andrews has given his Buy rating due to a combination of factors tied to Corteva’s stronger near‑term performance and improving earnings visibility. He highlights that first‑quarter EBITDA exceeded expectations and that management lifted first‑half EBITDA guidance, which captures the bulk of annual profits, implying the potential for a full‑year outlook upgrade once second‑half demand is clearer.
He also notes that both the seed and crop protection businesses outperformed on sales and margins, with the upside driven by gross profit strength rather than temporary cost cuts. In addition, tighter supply conditions in crop chemicals, particularly from constrained Chinese exports, are supporting firmer market pricing, creating a constructive backdrop that Corteva can monetize through a mix of volume and pricing, all of which underpins confidence in the stock’s upside potential.
In another report released today, Barclays also maintained a Buy rating on the stock with a $84.00 price target.
Based on the recent corporate insider activity of 67 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CTVA in relation to earlier this year.